Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Adc Therapeutics Sa
(NY:
ADCT
)
2.900
+0.030 (+1.05%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Adc Therapeutics Sa
< Previous
1
2
3
4
Next >
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
October 31, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
September 21, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
September 16, 2022
From
ADC Therapeutics SA
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
September 14, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
September 13, 2022
From
The Schall Law Firm
Via
Business Wire
ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference
September 06, 2022
From
ADC Therapeutics
Via
Business Wire
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes
August 15, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022
August 02, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
July 27, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
July 20, 2022
From
ADC Therapeutics SA
Via
Business Wire
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
July 11, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
July 08, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
July 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
June 29, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
June 13, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
June 10, 2022
From
ADC Therapeutics
Via
Business Wire
ADC Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
May 12, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces CEO Transition
May 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 04, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
May 03, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
April 04, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
March 17, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022
February 24, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report
February 17, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline
February 08, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Participate in Guggenheim Oncology Conference
February 02, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022
January 20, 2022
From
ADC Therapeutics
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.